JP2017519039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519039A5 JP2017519039A5 JP2017511547A JP2017511547A JP2017519039A5 JP 2017519039 A5 JP2017519039 A5 JP 2017519039A5 JP 2017511547 A JP2017511547 A JP 2017511547A JP 2017511547 A JP2017511547 A JP 2017511547A JP 2017519039 A5 JP2017519039 A5 JP 2017519039A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- collix
- toxin
- sequence number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 241001269314 Collix Species 0.000 claims 14
- 239000003053 toxin Substances 0.000 claims 14
- 231100000765 toxin Toxicity 0.000 claims 14
- 230000004927 fusion Effects 0.000 claims 13
- 230000000975 bioactive effect Effects 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 239000000969 carrier Substances 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000018997 Growth Hormone Human genes 0.000 claims 2
- 108010051696 Growth Hormone Proteins 0.000 claims 2
- 102000002265 Human Growth Hormone Human genes 0.000 claims 2
- 108010000521 Human Growth Hormone Proteins 0.000 claims 2
- 239000000854 Human Growth Hormone Substances 0.000 claims 2
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 2
- 102000001974 Hyaluronidases Human genes 0.000 claims 2
- 108010023197 Streptokinase Proteins 0.000 claims 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 2
- 229960005305 adenosine Drugs 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 229940088598 enzyme Drugs 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- 229960002773 hyaluronidase Drugs 0.000 claims 2
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960005202 streptokinase Drugs 0.000 claims 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 2
- 229960005356 urokinase Drugs 0.000 claims 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 1
- 102100036717 Growth hormone variant Human genes 0.000 claims 1
- 101710191157 Growth hormone variant Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102100039879 Interleukin-19 Human genes 0.000 claims 1
- 108050009288 Interleukin-19 Proteins 0.000 claims 1
- 102100030692 Interleukin-20 Human genes 0.000 claims 1
- 102100030703 Interleukin-22 Human genes 0.000 claims 1
- 102100036671 Interleukin-24 Human genes 0.000 claims 1
- 102100036679 Interleukin-26 Human genes 0.000 claims 1
- 101710181612 Interleukin-26 Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 102100022831 Somatoliberin Human genes 0.000 claims 1
- 101710142969 Somatoliberin Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 108090000681 interleukin 20 Proteins 0.000 claims 1
- 229940076144 interleukin-10 Drugs 0.000 claims 1
- 108010074109 interleukin-22 Proteins 0.000 claims 1
- 108090000237 interleukin-24 Proteins 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461990054P | 2014-05-07 | 2014-05-07 | |
| US61/990,054 | 2014-05-07 | ||
| PCT/US2015/029795 WO2015171965A2 (en) | 2014-05-07 | 2015-05-07 | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020147344A Division JP7125453B2 (ja) | 2014-05-07 | 2020-09-02 | 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519039A JP2017519039A (ja) | 2017-07-13 |
| JP2017519039A5 true JP2017519039A5 (enExample) | 2018-06-14 |
| JP6759188B2 JP6759188B2 (ja) | 2020-09-23 |
Family
ID=54393149
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511547A Active JP6759188B2 (ja) | 2014-05-07 | 2015-05-07 | 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子 |
| JP2020147344A Active JP7125453B2 (ja) | 2014-05-07 | 2020-09-02 | 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020147344A Active JP7125453B2 (ja) | 2014-05-07 | 2020-09-02 | 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子 |
Country Status (19)
| Country | Link |
|---|---|
| US (9) | US10624955B2 (enExample) |
| EP (2) | EP3998077B1 (enExample) |
| JP (2) | JP6759188B2 (enExample) |
| KR (2) | KR102598038B1 (enExample) |
| CN (2) | CN117298254A (enExample) |
| AU (2) | AU2015255834B2 (enExample) |
| BR (1) | BR112016025866A2 (enExample) |
| CA (1) | CA2948346C (enExample) |
| DK (1) | DK3139965T3 (enExample) |
| ES (1) | ES2900328T3 (enExample) |
| IL (2) | IL285716B (enExample) |
| MX (2) | MX385898B (enExample) |
| PH (2) | PH12016502447B1 (enExample) |
| PL (1) | PL3139965T3 (enExample) |
| PT (1) | PT3139965T (enExample) |
| RU (1) | RU2723178C2 (enExample) |
| SG (1) | SG11201610183XA (enExample) |
| SI (1) | SI3139965T1 (enExample) |
| WO (1) | WO2015171965A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2848656C (en) | 2010-09-15 | 2017-10-10 | Randall J. Mrsny | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| ES2900328T3 (es) | 2014-05-07 | 2022-03-16 | Applied Molecular Transport Inc | Moléculas de fusión derivadas de toxina Cholix para la administración oral de carga biológicamente activa |
| US10676723B2 (en) * | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2018075357A1 (en) | 2016-10-17 | 2018-04-26 | Duke University | PRODUCTION OF IMMUNOTOXIN D2C7-(scdsFv)-PE38KDEL |
| CA3093386A1 (en) * | 2018-03-08 | 2019-09-12 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
| KR20210076881A (ko) * | 2018-03-08 | 2021-06-24 | 어플라이드 몰레큘라 트랜스포트 인크. | 경구 전달용 독소-유래 전달 구조체 |
| EP3826682A4 (en) * | 2018-11-07 | 2021-11-17 | Applied Molecular Transport Inc. | CHOLIX-DERIVED MEDIA FOR ORAL HETEROLOGICAL LOADING ADMINISTRATION |
| SG11202104721RA (en) * | 2018-11-07 | 2021-06-29 | Applied Molecular Transport Inc | Delivery constructs for transcytosis and related methods |
| CN114206368A (zh) * | 2019-05-31 | 2022-03-18 | 横向知识产权私人有限公司 | 肽及其用途 |
| BR112022002962A2 (pt) | 2019-08-16 | 2022-07-05 | Applied Molecular Transport Inc | Composições, formulações e produção e purificação de interleucina |
| BR112022002975A2 (pt) * | 2019-08-16 | 2022-06-28 | Applied Molecular Transport Inc | Composições e partículas para aplicação de carga útil |
| US12122817B2 (en) * | 2020-09-22 | 2024-10-22 | Serpentide Inc. | Long-lasting GLP1 analogue drug for type-2 diabetes |
| IT202000028418A1 (it) * | 2020-11-25 | 2022-05-25 | Raicam Driveline S R L | Unità valvolare per un sistema di frenatura antibloccaggio |
| WO2023196532A1 (en) * | 2022-04-08 | 2023-10-12 | Applied Molecular Transport Inc. | Chimeric il-10/carrier constructs for treatment of pouchitis and methods of use |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1014372A (en) | 1910-12-01 | 1912-01-09 | Bush Mfg Company | Hinge. |
| US1013068A (en) | 1911-09-09 | 1911-12-26 | Frederick F Mcintosh | Single-trigger gun mechanism. |
| US2643653A (en) | 1951-07-19 | 1953-06-30 | Heidrich John | Pill injector |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| EP0092227B1 (en) | 1982-04-19 | 1988-07-27 | Nissan Motor Co., Ltd. | Method for controlling reduction ratio of continuously variable transmission with acceleration compensation |
| US5272065A (en) | 1983-10-20 | 1993-12-21 | Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| DE3680924D1 (de) | 1985-01-14 | 1991-09-26 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| US6051405A (en) | 1986-09-24 | 2000-04-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Constructs encoding recombinant antibody-toxin fusion proteins |
| US5807832A (en) | 1987-06-09 | 1998-09-15 | Biotech Australia Pty Limited | Oral delivery of biologically active substances bound to vitamin B12 |
| US5997856A (en) | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| EP0531434B1 (en) | 1990-05-11 | 1999-07-14 | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE | Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity |
| GB9112553D0 (en) | 1991-06-11 | 1991-07-31 | Wellcome Found | Fusion proteins |
| ATE158180T1 (de) | 1991-06-21 | 1997-10-15 | Univ Cincinnati | Oral verabreichbare therapeutische proteine und herstellungsverfahren |
| US6613332B1 (en) | 1991-06-21 | 2003-09-02 | The University Of Cincinnati | Oral administration of therapeutic proteins |
| US5487994A (en) * | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
| JP3553933B2 (ja) | 1992-06-18 | 2004-08-11 | アメリカ合衆国 | 高められた活性を有する組換シュードモナス外毒素 |
| CA2155005C (en) | 1993-02-02 | 1999-04-06 | Weldon Courtney Mcgregor | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
| GB9401787D0 (en) | 1994-01-31 | 1994-03-23 | Medeva Holdings Bv | Vaccine compositions |
| GB9320782D0 (en) | 1993-10-08 | 1993-12-01 | Univ Leeds Innovations Ltd | Stabilising of proteins on solution |
| GB9420355D0 (en) | 1994-10-10 | 1994-11-23 | Univ Nottingham | Preparation of protein microspheres, films and coatings |
| US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5922680A (en) | 1996-10-23 | 1999-07-13 | Ferring, B.V. | Stabilized composition for oral administration of peptides |
| AU740735B2 (en) | 1997-08-01 | 2001-11-15 | Toray Industries, Inc. | Method for stabilizing useful proteins and useful protein compositions |
| US6342611B1 (en) | 1997-10-10 | 2002-01-29 | Cytovia, Inc. | Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof |
| US6251392B1 (en) | 1997-10-20 | 2001-06-26 | Epicyte Pharmaceuticals, Inc. | Epithelial cell targeting agent |
| US6592847B1 (en) | 1998-05-14 | 2003-07-15 | The General Hospital Corporation | Intramolecularly-quenched near infrared flourescent probes |
| US7053200B1 (en) | 1999-06-01 | 2006-05-30 | Baylor College Of Medicine | Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation |
| CA2477857C (en) | 1999-10-04 | 2012-04-10 | Chiron Corporation | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| US20030186386A1 (en) * | 2000-02-11 | 2003-10-02 | Hansen Christian Karsten | Interleukin 10 |
| WO2003004055A2 (en) | 2000-11-27 | 2003-01-16 | Powderject Vaccines, Inc. | Nucleic acid adjuvants |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| US6573237B2 (en) | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
| EP1450855B1 (en) | 2001-05-23 | 2009-08-26 | Duotol Ab | Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| JP4623625B2 (ja) | 2003-07-24 | 2011-02-02 | 株式会社AMBiS | ヘテロ型５量体組換えワクチン |
| EP1522585A1 (en) | 2003-10-09 | 2005-04-13 | Plant Research International B.V. | Chimeric carrier molecules for the production of mucosal vaccines |
| SI1701968T1 (sl) * | 2003-12-17 | 2015-08-31 | Wyeth Llc | Imunogeni konjugati peptidnih nosilcev in postopek izdelave istih |
| US20080317761A1 (en) | 2004-04-28 | 2008-12-25 | The Trustees Of The University Of Pennsylvania | Peptide-Mediated Protein Transduction Into Cells of the Hematopoietic Lineage |
| US20050281885A1 (en) | 2004-06-21 | 2005-12-22 | Egilmez Nejat K | Method for treating inflammatory bowel disease by oral administration of IL-10 |
| US20090285771A1 (en) | 2004-10-04 | 2009-11-19 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of macromolecules |
| WO2006135428A2 (en) | 2004-10-04 | 2006-12-21 | Trinity Biosystems, Inc. | Methods and compositions for inducing an immune response against multiple antigens |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| ES2659039T3 (es) | 2005-07-29 | 2018-03-13 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services | Exotoxinas de pseudomonas mutadas con antigenicidad reducida |
| WO2007067597A2 (en) | 2005-12-05 | 2007-06-14 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of binding partners |
| CA2647168A1 (en) | 2006-03-16 | 2007-09-27 | Trinity Biosystems, Inc. | Methods for increasing the size of animals using needleless delivery constructs |
| EP2046375B1 (en) | 2006-07-20 | 2017-04-05 | The General Hospital Corporation | Methods and compositions for the selective activation of protoxins through combinatorial targeting |
| US20090092660A1 (en) | 2006-08-09 | 2009-04-09 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of particles |
| WO2008045486A2 (en) | 2006-10-09 | 2008-04-17 | The University Of North Carolina At Chapel Hill | Nanoparticle compositions for controlled delivery of nucleic acids |
| WO2008147526A1 (en) | 2007-05-23 | 2008-12-04 | The Trustees Of The University Of Pennsylvania | Targeted carriers for intracellular drug delivery |
| JP2010534061A (ja) | 2007-07-20 | 2010-11-04 | ザ ジェネラル ホスピタル コーポレイション | 組換えコレラ菌外毒素 |
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| WO2009026328A2 (en) | 2007-08-21 | 2009-02-26 | Immune Disease Institute, Inc. | Methods of delivery of agents to leukocytes and endothelial cells |
| WO2009115531A2 (en) | 2008-03-17 | 2009-09-24 | Universitätsklinikum Münster | Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions |
| WO2009149281A1 (en) | 2008-06-04 | 2009-12-10 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunotoxins and uses thereof |
| CA2739460C (en) | 2008-10-02 | 2019-05-21 | Emergent Product Development Seattle, Llc | Cd86 antagonist multi-target binding proteins |
| EP2456470A1 (en) | 2009-07-22 | 2012-05-30 | Cenix Bioscience GmbH | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
| WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| US11246915B2 (en) * | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| CA2848656C (en) | 2010-09-15 | 2017-10-10 | Randall J. Mrsny | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
| EP2667898A1 (en) * | 2011-01-26 | 2013-12-04 | Cenix Bioscience GmbH | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
| WO2012110596A1 (en) | 2011-02-16 | 2012-08-23 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Fusion protein for the treatment of immunologic or allergic reactions |
| WO2013003824A1 (en) | 2011-06-29 | 2013-01-03 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| CA2908208A1 (en) | 2013-04-24 | 2014-10-30 | Armo Biosciences, Inc. | Interleukin-10 compositions and uses thereof |
| CN112386680B (zh) | 2013-11-07 | 2024-05-24 | 纪念斯隆-凯特林癌病中心 | 在胃肠道移植物抗宿主病的治疗中使用il-22的方法 |
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| MX382229B (es) | 2014-01-27 | 2025-03-13 | Molecular Templates Inc | Polipéptidos que administran epítopos de cmh de clase i. |
| ES2900328T3 (es) | 2014-05-07 | 2022-03-16 | Applied Molecular Transport Inc | Moléculas de fusión derivadas de toxina Cholix para la administración oral de carga biológicamente activa |
| EP3209320B1 (en) | 2014-10-22 | 2023-03-08 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
| WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| CA3009127A1 (en) | 2016-01-06 | 2017-07-13 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating malignant, autoimmune and inflammatory diseases |
| EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| US11110122B2 (en) | 2016-06-03 | 2021-09-07 | New York University | Methods and reagents for modulating macrophage phenotype |
| WO2018005226A2 (en) | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| US11523772B2 (en) | 2016-12-14 | 2022-12-13 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
| WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| WO2018183931A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist |
| CA3093386A1 (en) | 2018-03-08 | 2019-09-12 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
| EP3826682A4 (en) | 2018-11-07 | 2021-11-17 | Applied Molecular Transport Inc. | CHOLIX-DERIVED MEDIA FOR ORAL HETEROLOGICAL LOADING ADMINISTRATION |
-
2015
- 2015-05-07 ES ES15788688T patent/ES2900328T3/es active Active
- 2015-05-07 EP EP21199457.9A patent/EP3998077B1/en active Active
- 2015-05-07 KR KR1020167034104A patent/KR102598038B1/ko active Active
- 2015-05-07 SG SG11201610183XA patent/SG11201610183XA/en unknown
- 2015-05-07 CN CN202311263281.5A patent/CN117298254A/zh active Pending
- 2015-05-07 WO PCT/US2015/029795 patent/WO2015171965A2/en not_active Ceased
- 2015-05-07 US US15/309,177 patent/US10624955B2/en active Active
- 2015-05-07 JP JP2017511547A patent/JP6759188B2/ja active Active
- 2015-05-07 AU AU2015255834A patent/AU2015255834B2/en active Active
- 2015-05-07 IL IL285716A patent/IL285716B/en unknown
- 2015-05-07 CN CN201580036678.8A patent/CN106470707A/zh active Pending
- 2015-05-07 CA CA2948346A patent/CA2948346C/en active Active
- 2015-05-07 DK DK15788688.8T patent/DK3139965T3/da active
- 2015-05-07 SI SI201531758T patent/SI3139965T1/sl unknown
- 2015-05-07 BR BR112016025866A patent/BR112016025866A2/pt not_active Application Discontinuation
- 2015-05-07 EP EP15788688.8A patent/EP3139965B1/en active Active
- 2015-05-07 KR KR1020237037526A patent/KR20230154480A/ko not_active Ceased
- 2015-05-07 PT PT157886888T patent/PT3139965T/pt unknown
- 2015-05-07 PL PL15788688T patent/PL3139965T3/pl unknown
- 2015-05-07 MX MX2016014548A patent/MX385898B/es unknown
- 2015-05-07 RU RU2016147734A patent/RU2723178C2/ru active
-
2016
- 2016-11-06 IL IL248768A patent/IL248768B/en unknown
- 2016-11-07 MX MX2021010666A patent/MX2021010666A/es unknown
- 2016-12-12 PH PH12016502447A patent/PH12016502447B1/en unknown
-
2017
- 2017-06-07 US US15/616,140 patent/US10130688B2/en active Active
-
2018
- 2018-10-04 US US16/151,533 patent/US10799565B2/en active Active
- 2018-12-03 US US16/207,655 patent/US10786555B2/en active Active
- 2018-12-03 US US16/207,611 patent/US10624956B2/en active Active
- 2018-12-03 US US16/207,637 patent/US10624957B2/en active Active
- 2018-12-14 US US16/220,923 patent/US10786556B2/en active Active
-
2020
- 2020-07-20 AU AU2020207779A patent/AU2020207779A1/en not_active Abandoned
- 2020-08-19 US US16/997,781 patent/US20210205420A1/en not_active Abandoned
- 2020-09-02 JP JP2020147344A patent/JP7125453B2/ja active Active
-
2021
- 2021-05-24 PH PH12021551189A patent/PH12021551189A1/en unknown
-
2023
- 2023-04-06 US US18/131,560 patent/US20240226243A9/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519039A5 (enExample) | ||
| US9358308B2 (en) | Compositions of a peptide targeting system for treating cancer | |
| Nowakowski et al. | Engineered mesenchymal stem cells as an anti-cancer trojan horse | |
| JP2019524721A (ja) | キメラ抗原受容体および使用方法 | |
| KR102741572B1 (ko) | 조직에서 코딩 리보핵산의 표적화된 전달, 발현 및 조절을 위한 조성물 및 방법 | |
| KR20200123139A (ko) | 코딩 리보핵산의 기관 보호적 발현 및 조절을 위한 조성물 및 방법 | |
| JP2019528044A (ja) | Ｍｕｃ１に特異的なキメラ抗原受容体（ｃａｒｓ）およびその使用方法 | |
| JP2020521445A5 (enExample) | ||
| MXPA06004199A (es) | Terapia en combinacion. | |
| US20220062383A1 (en) | Regulation of a foreign body response | |
| CN120769913A (zh) | 基于核酸的癌症疫苗及其方法 | |
| CN113039194A (zh) | 具有免疫调节特性的肽 | |
| US20180117176A1 (en) | Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumor immunity | |
| WO2015128651A1 (en) | Nucleic acids, and uses thereof | |
| RU2803294C2 (ru) | Композиции и способы органно-защитной экспрессии и модуляции кодирующих рибонуклеиновых кислот | |
| Wang et al. | A Combinatorial mRNA Therapy for Treating Rheumatoid Arthritis and Osteoarthritis by Inhibiting Inflammation and Promoting Cartilage Regeneration | |
| Han et al. | 270. Nanoparticle-Mediated Rhodopsin cDNA But Not the Intron-Containing DNA Delivery Causes Transgene Silencing in a Rhodopsin Knockout Model | |
| HK40022397A (en) | Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue | |
| HK40022397B (en) | Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue |